Objectives: Insulin-like growth factor 1 (IGF-1) is an important growth and anti-apoptotic factor for the cancer cells in several malignancies. IGF binding protein-3 (IGFBP-3) also apparently inhibits growth and induces apoptosis through IGF-independent mechanisms. In this study it was aimed to measure serum IGF-1 and IGFBP-3 levels in 25 patients with non-Hodgkin’s lymphoma and to compare with these results to healthy controls, and it was also aimed association between these results and some prognostic factors. Materials and Methods: Twenty five patients with non-Hodgkin’s lymphoma (NHL) whose age ranging from 18-63 (mean ± SE 40 ± 16.19) and 25 healthy volunteer whose age ranging from 18 to 63 (mean ± SE 40 ± 16.27) were obtained in Hematology and Oncology Department. Blood samples were collected and separated serums stored in –800C until study. IGF-1 ve IGFBP-3 levels were measured with immunofluorescence assay (IFA) and immunoradiometric assay (IRMA) (respectively). Results: IGF-1 level was higher in patients with NHL (mean±SE;357.88±197.45 ng/ml) than in healthy volunteer group (332.47±140.51 ng/ml), but this difference was not statistically significance (p>0.05). IGFBP-3 level was lower in patients with NHL (mean±SE; 1753.14±603.58 ng/ml) than in healthy volunteer group (1842.84±403.33 ng/ml), but this difference was not statistically significance (p>0.05). IGFBP-3 level in patients with B symptoms (1577.35±582.52 ng/ml) was significantly lower than in patients without B symptoms (2065.66±533.86 ng/ml) (p
Jerome L, Shiry L, Jones BL. Deregulation of the IGF axis in cancer: epidemiological evidence and potential therapeutic interventions. Endocr Relat Cancer 2003; 10: 561-578.
Giovannucci E. Insulin-like growth factor-I and their binding protein-3 and risk of cancer. Hormone Research 1999; 51: 34-41.
LeRoith D, Baserga R, Helman L, Charles T. Roberts Jr. Insulin- like Growth Factors and Cancer. Ann Intern Med 1995; 122: 54- 59.
Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 2000; 183: 1-9.
Czech MP. Signal transmission by the IGF’s. Cell 1989; 59: 235- 238.
Wu X, Yu H, Amos C, Hong W, Spitz M. Joint effect of insulin- like growth factors and mutagen sensitivity in lung cancer risk. J Natl Cancer Inst 2000; 92: 737-743.
Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF- binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 2000; 85: 4258- 4265.
Wolk A, Mantzoros CS, Andersson SO, et al. Insulin-like growth factor I and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998; 90: 911-915.
Aksoy Y, Aksoy H, Bakan E, Atmaca AF, Akçay F. Serum insulin-like growth factor-I and insülin-like binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia. Urol Int 2004; 72: 62-65.
Yu H, Spitz MR, Mistry J, Gu J, Hong, WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case- control analysis. J Natl Cancer Inst 1999; 91: 151-156.
Lukanova A, Lundin E, Toniolo P, Micheli A, Akhmedkhanov A, Rinaldi S, Muti P, Lenner P, Biessy C, Krogh V, Zeleniuch- Jacquotte A, Berrino F, Hallmans G, Riboli E, Kaaks R. Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int J Cancer 2002; 101: 549-554.
Ayabe T, Tsutsumi O, Sakai H, Yoshikawa H, Yano T, Kurimoto F, Taketani Y. Increased circulating levels of insulin-like growth factor-I and decreased circulating levels of insulin-like growth factor binding protein-1 in postmenopausal women with endometrial cancer. Endocr J 1997; 44: 419-424.
Steller MA, Delgado CH, Bartels CJ, Woodworth CD, Zou Z. Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res 1996; 56: 1761-1765.
Lee DY, Yang DH, Kang CW, Kim SJ, Joo CU, Cho SC, Kim JS. Serum Insulin-like Growth Factors (IGFs) and IGF Binding Protein (IGFBP)-3 in Patients with Gastric Cancer: IGFBP-3 protease activity induced by surgery. JKMS 1997: 12: 32-39.
Molica S, Vitelli G, Mirabelli R, et al. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression. Eur J Haematol 2006; 76: 51-57.
Çömlekçi A. Doku büyüme faktörleri ve eikozanoidler. İçinde: Kabalak T, Yılmaz C, Tüzün M (yazarlar). Endokrinoloji El Kitabı. İzmir: İzmir Güven Kitabevi, 2004: 45-59.
Reiter EO, Rosenfeld RG. Normal and aberant growth. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS (eds). Williams Textbook of Endocrinology. Philadelphia: Saunders, 2003: 1016- 1031.
Kabul Tarihi: 18.02.2006
Non-Hodgkin Lenfomalı Hastalarda IGF-1 ve IGFBP-3 Düzeyleri
Year 2006,
Volume: 11 Issue: 2, 98 - 102, 01.04.2006
Amaç: İnsülin benzeri büyüme faktörü (IGF), bir çok kanser türünde kanser hücreleri için önemli bir büyüme ve antiapopitotik faktördür. İnsülin benzeri büyüme faktörü bağlayıcı protein-3 (IGFBP-3) ise IGF-1 den bağımsız apopitozisi uyarır ve büyümeyi inhibe eder. Bu çalışmada serum IGF- 1 ve IGFBP-3 düzeylerine bakmayı, sağlıklı kontrol ile karşılaştırmayı ve bazı prognostik faktörlerle ilişkilerini araştırmayı amaçladık. Gereç ve Yöntem: Hematoloji ve Onkoloji Bilim Dallarında non Hodgkin lenfoma (NHL) tanısı konan ve yaşları 18-63 (ortalama 40±16.19) arasında olan 25 olgu ile, 18-63 yaşları arasında olan 25 sağlıklı gönüllüden 8-10 ml venöz kan alındı. Santrifüj edilen kanların serumları ayrılarak çalışma gününe kadar -800C de derin dondurucuda bekletildi. Hasta ve kontrol serumlarından IGF-1 ve IGFBP-3 ölçümleri immunoflorasan assay (IFA) ve immunoradyometrik assay (IRMA) yöntemleri ile yapıldı. Bulgular: Hasta grubunun serum IGF-I düzeyi (357.88±197.45 ng/ml) kontrol grubuna (332.47±140.51 ng/ml) göre yüksek olmasına rağmen bu fark istatistiksel olarak anlamlı değildi (p>0.05). Hasta grubunun IGFBP-3 (1753.14±603.58 ng/ml) düzeyleri kontrol grubuna (1842.84±403.33 ng/ml) göre düşük olmasına rağmen bu fark da istatistiksel olarak anlamlı değildi (p>0.05). IGFBP-3 düzeyi B semptomu olan hastalarda (1577.35±582.52 ng/ml) B semptomu olmayanlara(2065.66±533.86 ng/ml) göre daha düşük olarak bulundu (p
Jerome L, Shiry L, Jones BL. Deregulation of the IGF axis in cancer: epidemiological evidence and potential therapeutic interventions. Endocr Relat Cancer 2003; 10: 561-578.
Giovannucci E. Insulin-like growth factor-I and their binding protein-3 and risk of cancer. Hormone Research 1999; 51: 34-41.
LeRoith D, Baserga R, Helman L, Charles T. Roberts Jr. Insulin- like Growth Factors and Cancer. Ann Intern Med 1995; 122: 54- 59.
Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 2000; 183: 1-9.
Czech MP. Signal transmission by the IGF’s. Cell 1989; 59: 235- 238.
Wu X, Yu H, Amos C, Hong W, Spitz M. Joint effect of insulin- like growth factors and mutagen sensitivity in lung cancer risk. J Natl Cancer Inst 2000; 92: 737-743.
Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF- binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 2000; 85: 4258- 4265.
Wolk A, Mantzoros CS, Andersson SO, et al. Insulin-like growth factor I and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998; 90: 911-915.
Aksoy Y, Aksoy H, Bakan E, Atmaca AF, Akçay F. Serum insulin-like growth factor-I and insülin-like binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia. Urol Int 2004; 72: 62-65.
Yu H, Spitz MR, Mistry J, Gu J, Hong, WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case- control analysis. J Natl Cancer Inst 1999; 91: 151-156.
Lukanova A, Lundin E, Toniolo P, Micheli A, Akhmedkhanov A, Rinaldi S, Muti P, Lenner P, Biessy C, Krogh V, Zeleniuch- Jacquotte A, Berrino F, Hallmans G, Riboli E, Kaaks R. Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int J Cancer 2002; 101: 549-554.
Ayabe T, Tsutsumi O, Sakai H, Yoshikawa H, Yano T, Kurimoto F, Taketani Y. Increased circulating levels of insulin-like growth factor-I and decreased circulating levels of insulin-like growth factor binding protein-1 in postmenopausal women with endometrial cancer. Endocr J 1997; 44: 419-424.
Steller MA, Delgado CH, Bartels CJ, Woodworth CD, Zou Z. Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res 1996; 56: 1761-1765.
Lee DY, Yang DH, Kang CW, Kim SJ, Joo CU, Cho SC, Kim JS. Serum Insulin-like Growth Factors (IGFs) and IGF Binding Protein (IGFBP)-3 in Patients with Gastric Cancer: IGFBP-3 protease activity induced by surgery. JKMS 1997: 12: 32-39.
Molica S, Vitelli G, Mirabelli R, et al. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression. Eur J Haematol 2006; 76: 51-57.
Çömlekçi A. Doku büyüme faktörleri ve eikozanoidler. İçinde: Kabalak T, Yılmaz C, Tüzün M (yazarlar). Endokrinoloji El Kitabı. İzmir: İzmir Güven Kitabevi, 2004: 45-59.
Reiter EO, Rosenfeld RG. Normal and aberant growth. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS (eds). Williams Textbook of Endocrinology. Philadelphia: Saunders, 2003: 1016- 1031.
Keleş, M., Gündoğdu, M., Erdem, F., Türkeli, M., et al. (2006). Non-Hodgkin Lenfomalı Hastalarda IGF-1 ve IGFBP-3 Düzeyleri. Fırat Tıp Dergisi, 11(2), 98-102.
AMA
Keleş M, Gündoğdu M, Erdem F, Türkeli M, Yıldız L, Turhan H. Non-Hodgkin Lenfomalı Hastalarda IGF-1 ve IGFBP-3 Düzeyleri. Fırat Tıp Dergisi. April 2006;11(2):98-102.
Chicago
Keleş, Mustafa, Mehmet Gündoğdu, Fuat Erdem, Mehmet Türkeli, Leyla Yıldız, and Hamdullah Turhan. “Non-Hodgkin Lenfomalı Hastalarda IGF-1 Ve IGFBP-3 Düzeyleri”. Fırat Tıp Dergisi 11, no. 2 (April 2006): 98-102.
EndNote
Keleş M, Gündoğdu M, Erdem F, Türkeli M, Yıldız L, Turhan H (April 1, 2006) Non-Hodgkin Lenfomalı Hastalarda IGF-1 ve IGFBP-3 Düzeyleri. Fırat Tıp Dergisi 11 2 98–102.
IEEE
M. Keleş, M. Gündoğdu, F. Erdem, M. Türkeli, L. Yıldız, and H. Turhan, “Non-Hodgkin Lenfomalı Hastalarda IGF-1 ve IGFBP-3 Düzeyleri”, Fırat Tıp Dergisi, vol. 11, no. 2, pp. 98–102, 2006.
ISNAD
Keleş, Mustafa et al. “Non-Hodgkin Lenfomalı Hastalarda IGF-1 Ve IGFBP-3 Düzeyleri”. Fırat Tıp Dergisi 11/2 (April 2006), 98-102.
JAMA
Keleş M, Gündoğdu M, Erdem F, Türkeli M, Yıldız L, Turhan H. Non-Hodgkin Lenfomalı Hastalarda IGF-1 ve IGFBP-3 Düzeyleri. Fırat Tıp Dergisi. 2006;11:98–102.
MLA
Keleş, Mustafa et al. “Non-Hodgkin Lenfomalı Hastalarda IGF-1 Ve IGFBP-3 Düzeyleri”. Fırat Tıp Dergisi, vol. 11, no. 2, 2006, pp. 98-102.
Vancouver
Keleş M, Gündoğdu M, Erdem F, Türkeli M, Yıldız L, Turhan H. Non-Hodgkin Lenfomalı Hastalarda IGF-1 ve IGFBP-3 Düzeyleri. Fırat Tıp Dergisi. 2006;11(2):98-102.